Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

QR Code

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Yuya Seko,1 Taichiro Nishikawa,1 Atsushi Umemura,1 Kanji Yamaguchi,1 Michihisa Moriguchi,1 Kohichiroh Yasui,1 Mayumi Kimura,2 Hiroaki Iijima,3 Toshio Hashimoto,3 Yoshio Sumida,4 Takeshi Okanoue,5 Yoshito Itoh1 1Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine,...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2018
Sujets:	canagliflozin Japanese NASH fibrosis stages SGLT2 inhibitor type 2 diabetes mellitus Specialties of internal medicine RC581-951
Accès en ligne:	https://doaj.org/article/bfba1e10d95f4001b5ead934038fdfe6
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Canagliflozin review – safety and efficacy profile in patients with T2DM
par: Jakher H, et autres
Publié: (2019)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
par: Simes BC, et autres
Publié: (2019)

Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
par: Nina A. Petunina, et autres
Publié: (2016)

Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
par: Takahara M, et autres
Publié: (2020)

Study of Cytochrome P450 2E1 and its allele Variants in Liver Injury of Nondiabetic, Nonalcoholic Steatohepatitis Obese Women
par: VARELA,NELSON M, et autres
Publié: (2008)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
par: Davies MJ, et autres
Publié: (2017)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
par: A. V. Simanenkova, et autres
Publié: (2021)

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
par: Kawarasaki S, et autres
Publié: (2020)

Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial
par: Alam S, et autres
Publié: (2018)

Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis
par: Sandip Mukherjee, et autres
Publié: (2021)

Statins in Non-alcoholic Steatohepatitis
par: Jose D. Torres-Peña, et autres
Publié: (2021)

SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic SteatohepatitisSummary
par: Carmelo Luci, et autres
Publié: (2022)

Cetosis normoglicémica en adolescente con diabetes tipo 1 recibiendo insulina y dapaglifozina: Reporte de un caso
par: Pereyra A,Marcia, et autres
Publié: (2017)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
par: Liu S, et autres
Publié: (2019)

Bile acids contribute to the development of non-alcoholic steatohepatitis in mice
par: Justine Gillard, et autres
Publié: (2022)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
par: Jadwiga Nessler
Publié: (2021)

Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis
par: Li Y, et autres
Publié: (2019)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
par: Santos Cavaiola T, et autres
Publié: (2018)

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
par: Ganguli S, et autres
Publié: (2019)

Polypharmacology of clinical sodium glucose co‐transport protein 2 inhibitors and relationship to suspected adverse drug reactions
par: Karan Matharu, et autres
Publié: (2021)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
par: Shen L, et autres
Publié: (2021)

DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS
par: Marina V. Shestakova
Publié: (2019)

Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension
par: Silvie Hojná, et autres
Publié: (2021)

Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
par: Liu Y, et autres
Publié: (2021)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
par: Olga Yuryevna Sukhareva, et autres
Publié: (2016)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
par: Avgerinos I, et autres
Publié: (2019)

Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates
par: Philippe Garteiser, et autres
Publié: (2021)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
par: Muhammad Afzal, et autres
Publié: (2021)

Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice
par: Jiang YK, et autres
Publié: (2019)

Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice
par: David-Silva A, et autres
Publié: (2020)

Empagliflozin in type 1 diabetes
par: Mathieu C, et autres
Publié: (2019)

12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus
par: Perna S, et autres
Publié: (2018)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
par: Ahmadieh H, et autres
Publié: (2017)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
par: Aurélie Pahud de Mortanges, et autres
Publié: (2021)

Glucose and other hexoses transporters in marine invertebrates: A mini review
par: Martínez-Quintana,José Alfredo, et autres
Publié: (2012)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
par: Kuecker CM, et autres
Publié: (2016)

Is cancer incidence modified by SGLT2 inhibitors?
par: Lev M. Berstein
Publié: (2019)

Involvement of Intestinal Goblet Cells and Changes in Sodium Glucose Transporters Expression: Possible Therapeutic Targets in Autistic BTBR T<sup>+</sup>Itpr3<sup>tf</sup>/J Mice
par: Caterina Franco, et autres
Publié: (2021)

Association between Equol Production Status and Nonalcoholic Steatohepatitis
par: Takemi Akahane, et autres
Publié: (2021)

Empagliflozin: a new strategy for nephroprotection in diabetes
par: Anton Ivanovich Korbut, et autres
Publié: (2017)